Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma (MIC-VADS)
Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments (mutilating surgery, radiotherapy, chemotherapy). Major risk factors, tobacco and alcohol, create a chronic inflammatory environment promoting tumor development. The upper aerodigestive tract microbiome, influenced by these exposures and local alterations (necrosis, bleeding, ulcerations), is emerging as a potential factor in tumor progression, severity biomarker, or therapeutic target, though its exact role (cause or consequence) remains to be elucidated
Objectives:
- Primary: Compare bacterial microbiome composition between tumor tissue, adjacent healthy mucosa, and pharyngeal secretions
- Secondary:
- Correlate microbiome diversity/composition with clinical and epidemiological characteristics
- Identify microbiome variations by tumor stage, histology, and infiltration
- Discover diagnostic/prognostic microbial markers
- Analyze somatic variants (SNP/CNV) via whole-genome sequencing (WGS) and their association with microbiome profiles and clinical parameters
Study Design: Prospective, cross-sectional study with paired design (each patient serves as their own control to minimize genetic variation biases)
Methods:
- Samples: Tumor, adjacent healthy tissue, and pharyngeal secretions (3 samples/patient)
- Sequencing: Metagenomic sequencing (complete bacterial genomes) when biomass permits, or targeted 16S rRNA sequencing to identify dominant genera.
- Pilot study: 20 patients to select the optimal technique and validate feasibility, particularly assessing DNA quantity in these low-biomass environments
Population: Adults with suspected HNSCC scheduled for panendoscopy
Exclusion criteria: Recent antibiotics/corticosteroids (12 weeks), immunosuppression (uncontrolled HIV, active hematologic malignancies, autoimmune diseases on immunosuppressants, organ/stem cell transplants, uncontrolled diabetes), immunomodulatory treatments (3 months), recurrence, pregnancy, non-French speakers, legal guardianship, or lack of social security.
Safety: No additional risks beyond standard panendoscopy.
Expected impact: This approach may pave the way for innovative diagnostic or therapeutic strategies based on microbiome modulation in HNSCC.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Caroline TOURTE
- 電話番号:+33 01 61 69 31 50
- メール:caroline.tourte@chsf.fr
研究連絡先のバックアップ
- 名前:Renato TORRES, MD
- 電話番号:+33 01 61 69 34 59
- メール:renato.torres-lazo@chsf.fr
研究場所
-
-
France
-
Corbeil-Essonnes、France、フランス、91100
- Centre Hospitalier Sud Francilien
-
コンタクト:
- Renato TORRES, MD
- 電話番号:+33 01 61 69 34 59
- メール:renato.torres-lazo@chsf.fr
-
主任研究者:
- Renato TORRES, MD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult patient
- Consultation in the ENT department for suspected squamous cell carcinoma of the upper aerodigestive tract scheduled for panendoscopy
- Patient has provided consent to participate in the study and signed an informed consent form
Exclusion Criteria:
- Antibiotic or corticosteroid therapy within 12 weeks prior to consultation
Conditions associated with immunosuppression:
- Uncontrolled HIV infection (CD4 < 200 cells/µL) (permanent exclusion)
- Hematologic malignancies currently under treatment or not in complete remission for <2 years
- Autoimmune diseases under immunosuppressive treatment
- Solid organ or stem cell transplant recipients (permanent exclusion)
- Poorly controlled diabetes (HbA1c > 9%)
Immunomodulatory treatment within 3 months prior to consultation:
- Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4)
- Biotherapy targeting the immune system (anti-TNF, anti-IL, calcineurin inhibitors, antimetabolites)
- Recurrent upper aerodigestive tract cancer previously treated with surgery and/or radiochemotherapy
- Pregnancy (confirmed prior to panendoscopy)
- Patient who does not speak or understand French
- Subject under guardianship or curatorship
- Subject not affiliated with the national health insurance system
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Microbiome in head and neck squamous cell carcinoma Patients
Patients with suspected head and neck squamous cell carcinoma undergoing panendoscopy with additional biopsy sampling of tumor tissue, adjacent healthy mucosa, and pharyngeal secretions for microbiome analysis
|
Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:
These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention. Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:
These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
The difference in bacterial composition between the tumor, healthy mucosa, and hypopharyngeal secretions will be assessed
時間枠:at day 1
|
at day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlations between tumor microbiome diversity and composition and clinical/epidemiological data
時間枠:at day 1
|
tumor microbiome diversity (by sequencing) tumor microbiome composition (by sequencing)
|
at day 1
|
|
Differences in the tumor microbiome between subgroups defined by tumor stage, histological type, or infiltration, using differentiation tests
時間枠:at day 1
|
at day 1
|
|
|
Differential bacterial genera or strains between tumor, healthy, and pharyngeal microbiomes
時間枠:at day 1
|
at day 1
|
協力者と研究者
捜査官
- スタディディレクター:Béatrice SEGURENS、Phd, HDR
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。